Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843894 | 0.89 | GPR119 (0.49) | GPR119GPR183KCNH2 | |
| SCHEMBL1847026 | 0.89 | GPR119 (0.49) | GPR119GPR183KCNH2 | |
| SCHEMBL2371050 | 0.89 | GPR119 (0.49) | GPR119GPR183KCNH2 | |
| SCHEMBL2217567 | 0.88 | GPR119 (0.49) | GPR119GPR183KCNH2 | |
| SCHEMBL1843250 | 0.87 | GPR119 (0.48) | GPR119GPR183KCNH2 | |
| SCHEMBL2215847 | 0.87 | GPR119 (0.50) | GPR119GPR183KCNH2 | |
| SCHEMBL2371173 | 0.85 | GPR119 (0.64) | GPR119GPR183KCNH2 | |
| SCHEMBL2216969 | 0.84 | GPR119 (0.40) | GPR119GPR183HRH3JAK2JAK3 | |
| SCHEMBL2371302 | 0.83 | GPR119 (0.49) | GPR119GPR183KCNH2 | |
| SCHEMBL2215285 | 0.78 | GPR119 (0.39) | GPR119GPR183HRH3JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178054-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178054-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | GPR119 1/4885GPR183 27/4885HRH3 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.